The pressor effects to bolus doses of the a2-adrenoceptor agonist UK-14,304 were studied in the isolated vascular bed of the perfused rat tail before and after increasing the perfusion pressure with infusions of endothelin-1. Those of neuropeptide Y were studied before and after pre-constriction with endothelin-1 or 5-hydroxytryptamine. The pressor effects of neuropeptide Y were studied before and after functional disruption of the endothelium with the detergent CHAPS. 2 Endothelin-1 and the ax-adrenoceptor agonist phenylephrine induced dose-dependent vasoconstriction, endothelin-1 being some 104 times more potent than phenylephrine [log dose (mol) of the ED50 for endothelin-l and phenylephrine: -11.8 + 0.2 (n = 7), -8.2 + 0.2 (n = 5) respectively]. 3 Under control conditions, at basal perfusion pressures, UK-14,304 and neuropeptide Y were virtually inactive as vasoconstrictors. Following a sustained increase in perfusion pressure by infusions of endothelin-1 (2.5-10nM at 0.8mlmin-1), however, both UK-14,304 and neuropeptide Y induced dosedependent pressor responses and both were some 102 times more potent than phenylephrine [log dose 4 Pre-constriction-induced pressor responses to UK-14,304 were inhibited by 1 pM rauwolscine whilst those to neuropeptide Y were inhibited by disruption of the endothelium. Removal of the endothelium had no significant effect on the pressor responses to 4pmol or 8pmol endothelin-1 and had no effect on the increase in perfusion pressure induced by the endothelin-1 infusions but did decrease the time-course of pressor responses to bolus injections of endothelin-1. Endothelial disruption had no significant effect on the vasoconstriction induced by all but one of the doses of phenylephrine administered [log dose (mol) of the ED5o for phenylephrine after CHAPS: -8.6 + 0.2 (n = 5)], indicating that the responsiveness of the vascular smooth muscle was not destroyed by CHAPS. This treatment did, however, slow the onset and prolong the time course of the phenylephrine-induced responses. 5 These results indicate that, in the isolated vascular bed of the rat tail, pressor responses to both a2-adrenoceptor-and neuropeptide Y receptor-activation are uncovered by agonist-induced preconstriction including that to endothelin-1. Neuropeptide Y-induced vasoconstriction was endotheliumdependent.
Introduction
The pithed rat demonstrates the existence of post-junctional a1-and a2-adrenoceptors in the vasculature, both of which contribute to systemic pressor responses (Drew & Whiting, 1979; Docherty et al., 1979; Docherty & McGrath, 1980) . Until recently, however, there were few in vitro examples of arterial vessels or resistance beds that possess functional populations of postjunctional a2-adrenoceptors sensitive to the selective a2-adrenoceptor antagonists yohimbine, rauwolscine and idazoxan and resistant to the selective a1-adrenoceptor antagonist prazosin. However, in the isolated vascular bed of the rat tail, rauwolscine-sensitive and prazosin-resistant a2-adrenoceptors were uncovered by increasing the vascular tone with arginine vasopressin (Templeton et al., 1989) . The ability to uncover postjunctional a2-adrenoceptor-mediated responses is not restricted to arginine vasopressin i.e. 'tone' induced by 5-hydroxytryptamine also uncovers responses to 304 in the isolated perfused rat tail (Templeton, 1988) ; prostaglandin F2. , phenylephrine, acetylcholine, 5-hydroxytryptamine and histamine in the canine portal vein uncover responses to the selective c2-adrenoceptor agonist B-HT 920 (Furuta, 1988) ; nonpressor doses of angiotensin II enhance responses to the selective CX2-adrenoceptor agonist 304 in the rabbit saphenous artery (Dunn et al., 1989) and in the canine plantaris artery, responses to B-HT 920 are uncovered in the Author for correspondence. presence of the calcium channel activator Bay K 8644 (Sulpizio & Hieble, 1987) .
Neuropeptide Y is co-stored with noradrenaline in the large dense cored vesicles of sympathetic nerve endings (Ekblad et al., 1984) and they are co-released from the sympathetic varicosities upon nerve stimulation (Lundberg et al., 1984) . Previous in vitro studies have shown that, like x2-adrenoceptor agonists, neuropeptide Y is not a potent vasoconstrictor in its own right , although low levels of neuropeptide Y can potentiate the vasoconstriction induced by noradrenaline, sympathetic nerve stimulation and other vasoconstrictor agents (Edvinsson et al., 1984; . Furthermore, in cat cerebral vessels and the pig spleen vasculature, it has been shown that neuropeptide Y and x2-adrenoceptor agonists share the ability to inhibit adenylate cyclase through a pertussis-toxin-sensitive mechanism and to decrease intracellular levels of adenosine 3':5'-cyclic monophosphate (cyclic AMP) (Fredholm et al., 1985; Lundberg et al., 1988) . We have therefore now investigated and compared the influence of agonist-induced tone on the vascular responses to neuropeptide Y and an a2-adrenoceptor agonist.
Endothelin-1 is a potent vasoconstrictor in several isolated veins and arteries (Yanagasawa et al., 1988; D'Orleans-Juste et al., 1988) and can facilitate pressor effects of noradrenaline in rabbit ear artery (Wong-Dusting et al., 1989) but little is known about its interaction with peripheral postjunctional CX2-adrenoceptor activity.
We have studied the interactions between endothelin-1, neuropeptide Y and the a2-adrenoceptor agonist 304 in the isolated vascular bed of the rat tail. Vasoconstrictor responses to UK-14,304 were studied in the presence of endothelin-1 induced tone and those to neuropeptide Y were studied in the presence of tone induced by both endothelin-1 and 5-hydroxytryptamine. Previous studies have suggested that neuropeptide Y-induced vasoconstriction is endotheliumdependent (Daly & Hieble, 1987; Hieble et al., 1989) and this was investigated here by disruption of the vascular endothelium of the rat tail vasculature with the detergent CHAPS.
Methods
Male Wistar rats (280-320 g) were killed by stunning followed by cervical dislocation. The ventral surface of the tail was shaved and the skin reflected for 3-5 cm around the proximal end of the tail. The tail artery was exposed with blunt forceps and cleaned of fat and connective tissue and cannulated with a polyethylene cannula. The tail was amputated by cutting through an intervertebral disc and placed on an elevated plastic platform allowing the arterial cannula to be connected to a perfusion circuit. The tail vasculature was perfused at a rate of 0.8mlmin-' with a modified physiological salt solution the temperature of which, at the point of entry into the tail artery, was monitored with a digital thermometer (Digitron Instrumentation Ltd) and maintained at 370C + 0.40C (n = 12). The temperature of the perfusate leaving the tail was also monitored and was found to be 26.50C + 0.3OC (n = 12) . After the start of perfusion, blood filled drops were observed from the cut end of the tail, indicating a successful cannulation. The perfusion pressure was allowed to stabilize for 45 min before the start of any experimental procedure.
Measurement of agonist-mediated responses at basal and raised perfusion pressure Dose-response curves to endothelin-1, neuropeptide Y, phenylephrine and UK-14,304 were constructed by bolus injection of drugs into the perfusing solution via an injection port close to the point of cannulation. The injectate volume was constant at 0.01 l1 and doses are expressed as quantity (nmol etc.).
Drugs added to the perfusate reservoir are expressed as concentration (nM etc.). In all experiments, the perfusion pressure was allowed to return to baseline before the administration of a subsequent dose of agonist. In those preparations in which endothelin-1 dose-response curves were constructed, the number of doses it was possible to administer in each was variable due to the long recovery period required for the higher doses. The actual doses administered to each tail were therefore variable and the 'n' values for each dose were correspondingly variable in these experiments (i.e. see Figure 5a ).
After establishing control responses to neuropeptide Y and UK-14,304, endothelin-1 (2.5-10nM) was included in the perfusate until the perfusion pressure was approximately doubled. After a stable perfusion pressure had been maintained over a O min period, dose-response curves for the two agonists were repeated. In other experiments, a dose-response curve to neuropeptide Y was determined before and after doubling the vascular perfusion pressure with 5-hydroxytryptamine (5-20 nM). The concentrations of endothelin-l and 5-hydroxytryptamine used were variable as the dose required to double the vascular perfusion pressure varied between preparations. In those preparations in which UK-14,304 was studied, after establishing the second doseresponse curve, 1 gM rauwolscine was added to the perfusate (still containing endothelin-1) and the dose-response curve for UK-14,304 repeated for a third time.
Effect of endothelium removal on neuropeptide Y-, endothelin-l-and phenylephrine-induced responses
In those preparations in which responses to neuropeptide Y were studied in the presence of endothelin-1, after establishing the second dose-response curve, destruction of the endothelium was achieved by perfusion of the vascular bed with 0.3% (w/v) solution of the detergent CHAPS in distilled water at 2mlmin-1 for 90s. The infusion of endothelin-1 was then immediately resumed. After a 30min re-equilibration period, the dose-response curve for neuropeptide Y (still in the presence of endothelin-1) was repeated for a third time. Removal of the endothelium was confirmed both histologically and pharmacologically. Histologically, the presence or absence of the endothelium was determined by use of cacodylate buffered fixative (Sabatini et al., 1963) on artery samples which were cut on a cryostat. Pharmacologically, in four preconstricted preparations, the effect of CHAPS on acetylcholine-induced vasorelaxation was determined as it is known that removal of the vascular endothelium abolishes endothelium-dependent vasorelaxation to acetylcholine.
In order to establish if treatment with CHAPS affected the responsiveness of the vascular smooth muscle and if the pressor effect of endothelin-1 was affected by such treatment, in those preparations in which dose-response curves for phenylephrine and endothelin-1 had been established, the responsiveness of the vasculature to these agonists was determined after CHAPS treatment.
Drugs and solutions
The composition of the physiological salt solution was (in mM): NaCl 118.4, NaHCO3 25, KCI 4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2 2.5, glucose 11 and Na2EDTA 0.023. Ficoll (2%, molecular weight approximately 70,000) was included to prevent water retention. The following compounds were used: rauwolscine HCI (Roth); UK-14,304 (5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline bitartrate, Pfizer); phenylephrine HCI (Sigma); 5-hydroxytryptamine creatinine sulphate, (BDH biochemicals); acetylcholine chloride (Sigma); CHAPS (3-[3-cholamidopropyl)-dimethylammonio]-1-propanesulphonate, Sigma); neuropeptide Y (I.C.I. Pharmaceuticals Division, Cheshire) and endothelin-1 (human, Scientific Marketing Associates).
Statistical analysis
All results are given as the mean + s.e.mean. The ED50s for the agonists were calculated for each individual preparation (by BBC microcomputer graphical interpolation) and meaned within groups. For all experiments, differences between means were compared by paired Student's t test. For those experiments in which the n for the first dose-response-curve was greater than that for the subsequent one to be compared, a paired Student's t test was applied only to those experiments in which both procedures were conducted, and it is these results which are given below.
Results
Pressor responses to 304 in the presence and absence ofendothelin-l-induced tone, and the effect of rauwolscine Figure 1 shows the vasoconstrictor responses to UK-14,304 at basal perfusion pressure and in the presence of endothelin-1-induced tone (in the absence and presence of 1 ,UM rauwolscine). At a basal perfusion pressure of 76 + 8 mmHg (n = 6), UK-14,304 produced a maximum response of only 6 mmHg. During an infusion of endothelin-1 (2.5-10nM), sufficient to double the perfusion pressure of each individual preparation (162 + 18 mmHg; n = 6), UK-14,304 elicited dose-dependent increases in perfusion pressure. The maximum response was approximately 90 mmHg and the log dose (mol) of the EDso for UK-14,304 was -10 + 0.5 (n = 6). which was significantly less than the maximum response attained (P < 0.05). Pressor responses to neuropeptide Y in the presence and absence ofendothelin-1-or 5-hydroxytryptamine-induced tone and the effect ofendothelium removal Figure 2a shows the vasoconstrictor responses to neuropeptide Y at basal perfusion pressure, after vascular tone was doubled with endothelin-1 and after removal of the endothelium with CHAPS (in the presence of endothelin-1). At a basal perfusion pressure of 72 + 7 mmHg (n = 6), neuropeptide Y failed to elicit a response greater than 14 + 6 mmHg. After vascular tone had been increased to 157 + 14mmHg (n = 6), neuropeptide Y induced a dose-dependent increase in perfusion pressure which returned to baseline in 10-40 min depending on the dose administered. The maximum response elicited was 110 mmHg and the log dose (mol) of the ED50 for neuropeptide Y was -10.3 + 0.4 (n = 6). In 3 experiments it was also confirmed that neuropeptide Y-induced responses were not affected by 1 fIM rauwolscine. Figure 2a shows that removal of the endothelium with CHAPS (still in the presence of endothelin-1) abolished all responses to neuropeptide Y. CHAPS treatment did not significantly affect the increase in vascular tone induced by the endothelin-1 infusion, the perfusion pressure after treatment with CHAPS being 129 + 16mmHg (n = 4). In 3 experiments it was also confirmed that CHAPS did not affect the ability of the rat tail vasculature to respond to 304 . Figure 2b shows the vascular responses to neuropeptide Y before (n = 6) and after increasing the vascular tone with 5-hydroxytryptamine [5-20nM] fore, not have been calculated from a true maximum and may be higher in value.
In 2 preparations in which vascular perfusion pressure was increased from mean values of 60 mmHg to 200 mmHg with 5 nM 5-hydroxytryptamine, acetylcholine (5.5 nmol) induced a vasorelaxation of 80 mmHg. This was abolished after perfusion of the preparation with CHAPS. Likewise, in 2 preparations in which tone was increased with 1 fIM phenylephrine (from means of 60mmHg to 150 mmHg) acetylcholine (5.5 nmol) induced an initial pressor response followed by a vasorelaxation (Figure 3a) . After CHAPS treatment the pressor response remained whilst the vasorelaxation was abolished ( Figure 3b ). This indicates that the endothelium was successfully removed with CHAPS but the ability of the smooth 
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. I-muscle to contract was not affected. Removal of the endothelium with CHAPS was also confirmed histologically.
Pressor responses to phenylephrine and endothelin-! and the effect ofendothelium removal Figure 4a shows the vasoconstrictor responses to the selective ,1-adrenoceptor agonist phenylephrine before (n = 5) and after perfusion of the tail vascular bed with CHAPS (n = 5). Before CHAPS infusion, the basal perfusion pressure was 69 + 6mmHg and phenylephrine produced a maximum response of 210 mmHg and its log dose (mol) of the ED50 was -8.2 + 0.2. Following phenylephrine administration, the perfusion pressure recovered after 1-15 min. Treatment with CHAPS did increase the perfusion pressure in some preparations (e.g. see Figure 4b ) but overall, had no statistically significant effect on the basal perfusion pressure of the CHAPS-treated group of preparations (93 + 11 mmHg), and no significant effect on the ability of the vascular bed to respond to phenylephrine (log dose (mol) of the ED5O for phenylephrine in the presence of CHAPS was -8.6 + 0.2) except at the 2 nmol dose. At this one dose, removal of the endothelium with CHAPS significantly decreased the phenylephrine-induced vasoconstriction. Removal of the endothelium slowed the onset and prolonged the time course of the phenylephrine response as depicted in Figure 4b .
Endothelin-1 induced dose-dependent vasoconstriction from a basal perfusion pressure of 73 + 5 mmHg (n = 5-9). Its maximum pressor response was 110 mmHg and the log dose (mol) of its ED50 was -11.8 + 0.2 (n = 7) [ Figure 5a ]. Perfusion pressure returned to baseline some 5-60 min after endothelin-1 administration, depending on the dose adminis- tered. Removal of the endothelium with CHAPS had no significant effect on the vascular responses to bolus injections of endothelin-1. With 4 pmol endothelin-1 the response before CHAPS was 51 + 9mmHg (n = 9) and after CHAPS was 40 + 8 mmHg (n = 5). With 8 pmol endothelin-l the response before CHAPS was 70 + 13 mmHg (n = 7) and after CHAPS was 127 + 27mmHg (n = 4). In 2 out of 4 of these preparations, the perfusion pressure was increased by CHAPS treatment and, in all 4, the time course of the endothelin-1 response was altered by removal of the endothelium, being slower in onset and shorter in duration ( Figure Sb) .
Discussion
The influence of vascular tone on a2-adrenoceptor-and neuropeptide Y-receptor-mediated vasoconstriction Under the control experimental conditions used here the temperature of the perfusate was decreased by 10.5°C on passage through the tail indicating that the vasculature was markedly vasodilated. This confirms the importance of the rat tal vasculature in thermoregulation (Rand et al., 1965; Raman et al., 1983 arginine vasopressin-induced tone will also uncover rauwolscine-sensitive, prazosin-resistant X2-adrenoceptormediated responses and has no effect on vascular responses to phenylephrine (Templeton et al., 1989) . Some previous studies using segments of the isolated tail artery of the rat and selective al-adrenoceptor and a2-adrenoceptor antagonists have indicated postjunctional CX2-adrenoceptor involvement in vasoconstriction induced by nerve stimulation or catecholamines (Medgett & Langer, 1984; de Moraes et al., 1988) . Raising the vascular tone with endothelin-1 not only uncovered responses to UK-14,304 but showed it to be some 102 times more potent than the a1-adrenoceptor agonist phenylephrine (as indicated by its ED50 value) though producing maximum responses some 50% of those elicited by phenylephrine. The responses to UK-14,304 were also of longer duration than those to phenylephrine. The highest dose of UK-14,304 induced a pressor response that was significantly less than the maximum response. The reason for this is unclear, though there is some evidence to suggest that in both un-constricted and preconstricted rat isolated tail arteries, high doses of a2-adrenoceptor agonists may induce release of an endothelium-dependent relaxing factor which counteracts their direct contractile activity (Matsuda et al., 1985) . At basal vascular tone, neuropeptide Y was virtually inactive at inducing pressor responses. However, in those vascular beds pre-constricted with endothelin-1, neuropeptide Y elicited dose-dependent vasoconstrictions. Like UK-14,304, neuropeptide Y induced a maximum response only 50% that of phenylephrine, was 102 times more potent than phenylephrine as indicated by its ED50 value and its responses were of a longer duration than those of phenylephrine. Pre-constriction with 5-hydroxytryptamine instead of endothelin-1 had a somewhat different effect on responses induced by neuropeptide Y. Although its ED50 value was not changed, in the presence of 5-hydroxytryptamine, neuropeptide Y elicited responses twice the magnitude of those elicited in the presence of endothelin. The results indicate that, in the perfused vascular bed of the rat tail, the magnitude of the response to neuropeptide Y depends upon the pre-constricting substance. Furuta (1988) also demonstrated that, in canine isolated portal vein, the a2-adrenoceptor agonist B-HT 920 failed to elicit responses at basal vascular tone but could induce concentration-dependent responses, the maxima of which depended both on the pre-contraction levels and on the precontracting substance.
Under conditions of increased sympathetic discharge such as occurs in hypertension, haemorrhagic shock and hypoxia, co-release of neuropeptide Y may contribute to the observed increases in regional resistance. That neuropeptide Y overflow is increased under conditions of increased sympathetic discharge is indicated by the observation that circulating neuropeptide Y levels increase following haemorrhage in rats (Morris et al., 1987) and exercise in man (Morris et al., 1986) . There is increasing evidence that, in man, circulating levels of endothelin-1 are raised in conditions in which regional vasoconstriction is increased such as in acute renal failure (Tomita et al., 1989 ) and essential hypertension (Saito et al., 1990) .
Recalculating the data in these studies shows that the circulating concentration of endothelin-1 is increased to approximately 1O pmol-1 nmol in such patients. This range of endothelin-1 concentration has been shown to be sufficient to induce contraction of human umbilical vessels in vitro (Haegerstrand et al., 1989) . Thus, combinations of increased sympathetic tone, increased circulating endothelin-1 and increased circulating neuropeptide Y levels may promote increased expression of prolonged a2-adrenoceptor-and neuropeptide Y-mediated regional vasoconstriction in such disease states.
Acetylcholine-induced vasorelaxations in the perfused rat tail are inhibited by both haemoglobin (an inhibitor of endothelium-dependent relaxing factor, Griffith et al., 1984) and atropine (Templeton, 1988) . Perfusion of blood vessels with the detergent CHAPS has been shown to remove the vascular endothelium without any significant effect upon the underlying vascular smooth muscle (Tesfamariam et al., 1984; Hiley et al., 1987) . In the tail bed, the vasoconstrictor responses to phenylephrine, endothelin-1 and acetylcholine were not significantly affected, whilst the vasorelaxation induced by acetylcholine was abolished by CHAPS. This proof of selective endothelium removal was supported by histological evidence of endothelial damage. The simplest explanation of these results is that, in the rat perfused tail, perfusion of CHAPS disrupts the vascular endothelium without affecting the underlying smooth muscle.
The neuropeptide Y-induced contractions in the presence of agonist-induced tone were not observed after endothelium removal. This is consistent with previous studies showing that neuropeptide Y-induced potentiation of adrenoceptormediated contractions in the rabbit ear artery and canine saphenous vein are endothelium-dependent (Daly & Hieble, 1987; Hieble et al., 1989) but contrary to other studies showing that the direct vasoconstrictor effect of neuropeptide Y on small human skeletal muscle arteries and pig splenic arteries is not endothelium-dependent (Pernow, 1989) . This indicates that there may be species or tissue differences in the endotheliumdependency of neuropeptide Y-induced responses. In the rat tail vasculature, it is possible that neuropeptide Y requires the presence of an endogenous endothelium-dependent constricting factor, such as endothelin, to elicit its vasoconstrictor response. The continuous infusion of endothelin-1 did not, however, permit neuropeptide Y-induced responses in the absence of endothelium. This could be because endothelin-1 is not the endogenous endothelium-dependent constricting factor involved in the neuropeptide Y response or that it is crucial for such a factor to be released endogenously from the endothelium to exert its permissive effect on the vascular smooth muscle. The actual endothelial mechanism of the neuropeptide Y response is currently under investigation. (Su et al., 1986; Abe et al., 1987) . Neuropeptide Y-induced vasoconstriction in human skeletal muscle and renal arteries is sensitive to nifedipine (Pernow, 1988) and in the pithed rat, neuropeptide Y-induced potentiation of aadrenoceptor activation is also Ca2+-dependent (Dahlof et al., 1985) .
The effect of endothelium removal on pressor responses induced by endothelin-I and phenylephrine
Removal of the endothelium with CHAPS did not significantly affect the maximum responses to phenylephrine or its ED50 and significantly reduced the response at only one indi-vidual dose. However, there is no positive evidence for endothelium-dependency of the phenylephrine-induced response. The effect of phenylephrine seems to be directly on the vascular smooth muscle and the ability of the vascular smooth muscle to contract is certainly not greatly affected by treatment with CHAPS. In some preparations, removal of the endothelium did increase the basal perfusion pressure. This could indicate a degree of tonic endothelium-derived relaxing factor release from the rat tail vasculature although, as this effect was not seen in all CHAPS-treated preparations, it may simply indicate a less specific 'damage'. More consistently, however, the time-course of the phenylephrine-induced response was markedly prolonged upon removal of the endothelium, usually by a factor of three and the onset of the response was slowed. Garland (1989) reported that, in the rabbit basilar artery, removal of the endothelium inhibited the production of phenylephrine-induced action potentials and that this was associated with a slower development in tension. A similar effect could explain the present increased timecourse of the response to phenylephrine after CHAPS. Alternatively, in the rat tail vasculature under normal circumstances, the responses to phenylephrine may be buffered by release of an endothelium-dependent relaxing factor and/or facilitated by an endothelium-dependent constricting factor. This is such a clear effect that it deserves further study.
The most potent agonist used in this study was endothelin-1, being 104 times more potent than phenylephrine and 102 times more potent than UK-14,304 and neuropeptide Y (even in the presence of vascular tone). This is consistent with its very high potency in most vascular preparations on which it has been tested (e.g. Yanagasawa et al., 1988; D'Orleans-Juste et al., 1988) . Removal of the endothelium did not significantly affect the responses to bolus injections of endothelin-1, although there was an increase in endothelin-1 infusioninduced perfusion pressure in some preparations following CHAPS treatment which may be due to the ability of prolonged infusions of endothelin-1 to induce release of endothelium-dependent relaxing factor from the intact endothelium (Warner et al., 1989) . As with phenylephrine, however, the evidence suggests that the vasoconstrictor effect of endothelin-I is via receptors located on the vascular smooth muscle. The time course of the endothelin-1 induced response was reduced by removal of the endothelium and this was associated with slower development of the pressor response. Again, this may indicate that, in the endothelium-intact rat tail vasculature some endothelium-dependent factor may contribute to the development and maintenance of endothelin-1-induced responses.
In conclusion, in the rat isolated tail vasculature, the a2-adrenoceptor agonist UK-14,304 did not induce vasoconstriction until the vascular tone of the preparation was increased with endothelin-1. Likewise, neuropeptide Y did not cause vasoconstriction until the vascular bed was preconstricted with either endothelin-1 or 5-hydroxytryptamine and the maximum response to neuropeptide Y was higher in the presence of 5-hydroxytryptamine. The neuropeptide Yinduced pressor responses were endothelium-dependent. It is suggested that a preconstriction-induced increase in [Ca2+] i is necessary for responses to these two agonists. The prolonged, and potent responses to CX2-adrenoceptor agonists and neuropeptide Y, uncovered in the presence of increased vascular tone, may contribute to regional vasoconstriction observed in pathological conditions in which sympathetic nerve activity is increased.
